Summary
Pancragen is a synthetic four-amino-acid peptide (Lys-Glu-Asp-Trp) from the Khavinson series of bioregulator peptides, designed from a peptide extract of pancreatic tissue. All published research is from the developing institute and none is in humans.
What it targets
In rats with chemically induced diabetes, oral Pancragen was associated with lower blood glucose and intramuscular Pancragen with normalised capillary endothelial adhesion. In nine old rhesus monkeys, a ten-day course lowered basal glucose and was associated with normalised insulin and C-peptide, compared with four animals given glimepiride; there was no untreated control group. In pancreatic cell cultures it increased expression of transcription factors that drive cell differentiation. A molecular-modelling paper proposes it binds DNA directly. The developers describe these as 'geroprotective' effects on the ageing pancreas; that framing is theirs.
Clinical Research
Suppliers stocking Pancragen
No listed suppliers stock this yet.